Boosting cancer-fighting T cells by targeting IL-1R1 signals
Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
This project aims to strengthen patients' CD8 T cells to fight cancer by tuning signals through a protein called IL-1R1.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11172632 on NIH RePORTER |
What this research studies
Researchers are studying two related immune signals, IL-1α and IL-1β, to understand how they help or hinder CD8 T cells that attack tumors. Using animal models and cellular experiments, they will tease apart how blocking IL-1β or engaging IL-1α changes immune responses in the tumor microenvironment. The team will examine effects on both T cells and myeloid cells to find ways to enhance anti-tumor immunity with fewer side effects. Findings could guide more precise therapies that boost T cell activity against solid tumors.
Who could benefit from this research
Good fit: Patients with solid tumors where CD8 (killer) T cells play a role, or people willing to donate tumor or blood samples for research, would be most relevant to this work.
Not a fit: People without cancer, those with cancers that do not rely on CD8 T cell responses, or those seeking an immediate treatment effect are unlikely to benefit directly from this preclinical research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to boost T cell–based anti-cancer immunity and improve immunotherapy effectiveness for some patients.
How similar studies have performed: Some prior human trials (for example CANTOS) and animal studies have hinted that targeting IL-1 pathways can affect cancer risk and immunity, but results have been mixed and the approach is still experimental.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Kupper, Thomas S. — Brigham and Women's Hospital
- Study coordinator: Kupper, Thomas S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.